Srinivasan Madhusudan

Has grant

Professor of Medical Oncology

University of Nottingham

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Srinivasan Madhusudan is a faculty member at the University of Nottingham, UK. His research areas focus on medical oncology, particularly in ovarian and breast cancers, emphasizing mechanisms of resistance to therapies and precision medicine strategies. Recent articles authored by Professor Madhusudan include studies on PARP inhibitors, the clinical significance of CDK2 in cancer, and targeting DNA damage repair in oncology.

Recent Grants

Grant: Close

Evaluation of SMUG1 (single-strand-selective monofuntional uracil-DNA glycosylase 1) for personalised treatment strategy in breast cancer

Open Date: 2012-08-01

Close Date: 2013-07-31

Articles (16)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (7)

Nigel Mongan

Professor of Oncology

University of Nottingham

UNITED KINGDOM

View details

Jennie Jeyapalan

Assistant Professor

University of Nottingham

UNITED KINGDOM

View details

Jenny Persson

Guest Professor

Malmö University

SWEDEN

View details

Melissa Davis

Professor and Director

Morehouse School of Medicine

UNITED STATES

View details

Nathan Archer

Assistant Professor (Epitranscriptomics)

University of Nottingham

UNITED KINGDOM

View details

Lodewijk Dekker

Associate Professor

University of Nottingham

UNITED KINGDOM

View details

Emad A Rakha

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Srinivasan Madhusudan

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (16)

Transcription Factor p73 Is a Predictor of Platinum Resistance and Promotes Aggressive Epithelial Ovarian Cancers

PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapy

Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers

The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers

Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade

Targeting DNA damage repair precision medicine strategies in cancer

The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers

Evaluation oncotype DX® 21‐gene recurrence score and clinicopathological parameters: a single institutional experience

Altered Regulation of the Glucose Transporter GLUT3 in PRDX1 Null Cells Caused Hypersensitivity to Arsenite

Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers

Evolving DNA repair synthetic lethality targets in cancer

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.

Towards Personalized Management of Ovarian Cancer

The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer

Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted

Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer

Collaborators (7)

Nigel Mongan

Jennie Jeyapalan

Jenny Persson

Melissa Davis

Nathan Archer

Lodewijk Dekker

Emad A Rakha

Make your next move.